Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica
Previous issue | Volume 26 | ECE2011 | Next issue

13th European Congress of Endocrinology

Poster Presentations

Pituitary

Previous section
Neuroendocrinology
Table of contents
Next section
Obesity

ea0026p191 | Pituitary

The treatment with dopamine agonists are not associated with increased prevalence of cardiac-valve regurgitation in patients with prolactinomas and acromegalia

ea0026p192 | Pituitary

Adipocytes as a source of increased circulating levels of NAMPT/visfatin in active acromegaly

ea0026p193 | Pituitary

Pituitary mycosis complicating a Cushing’s macroadenoma

ea0026p194 | Pituitary

Immunopositive ACTH cells in juvenile female rats after treatment with estradiol

ea0026p195 | Pituitary

A case of an ectopic prolactinoma

ea0026p196 | Pituitary

Coping strategies in patients after treatment for functioning or non-functioning pituitary adenomas

ea0026p197 | Pituitary

Polycystic ovary syndrome and prolactinoma association

ea0026p198 | Pituitary

Effects on metabolic parameters after 12-month treatment with a new once-a-week sustained release recombinant growth hormone (LB03002) in adult patients with GH deficiency (GHD)

ea0026p199 | Pituitary

Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency

ea0026p200 | Pituitary

Effects of 3-year GH replacement therapy on bone mineral density in younger and elderly adults with adult onset GH deficiency

ea0026p201 | Pituitary

Evaluation of aortic stiffness in the acromegaly patients with remission

ea0026p202 | Pituitary

Baseline characteristics and effects of 10 years of GH replacement therapy in adults previously treated with pituitary irradiation therapy

ea0026p203 | Pituitary

Effects of dopamine agonist on heart and lung in patients receiving dopamine agonist due to hyperprolactinemia

ea0026p204 | Pituitary

Efficacy of transsphenoidal surgery in treatment of Cushing’s disease: factors influencing postsurgical outcome

ea0026p205 | Pituitary

LHRH-antagonist cetrorelix may reduce postmenopausal flushing

ea0026p206 | Pituitary

O-6 methylguanine-DNA methyl transferase (MGMT) immunoexpression in GH secreting pituitary adenomas and it’s correlation with Ki-67 labeling index (Ki-67 LI)

ea0026p207 | Pituitary

Mechanism of anterior pituitary gene regulation by LHX3 in paediatric combined pituitary hormone deficiency

ea0026p208 | Pituitary

High risk of central adrenal insufficiency in GH deficient long-term survivors of childhood acute lymphoblastic leukaemia

ea0026p209 | Pituitary

Rationale and design of a global hyponatraemia registry

ea0026p210 | Pituitary

Screening of Cushing’s syndrome and Acromegaly in Japanese diabetic patients

ea0026p211 | Pituitary

Gender-related differences in prolactinomas

ea0026p212 | Pituitary

Efficacy and safety of the use of the recombinant GH receptor antagonist pegvisomant (PGV) in acromegaly. Evaluation of its use in 13 patients treated in a pituitary disorders unit

ea0026p213 | Pituitary

Hypothalamic tumor in a patient with Pendred syndrome

ea0026p214 | Pituitary

Multimodal treatment and minimally invasive surgery for 117 pituitary adenomas: a Croatian Pituitary Centre experience

ea0026p215 | Pituitary

Illness perceptions, quality of life and self-reported physical symptoms in patients after long-term remission of Cushing’s syndrome

ea0026p216 | Pituitary

Long-term treatment of acromegaly with pegvisomant (Somavert): cross-sectional observations from ACROSTUDY, a post-marketing, international, safety, surveillance study

ea0026p217 | Pituitary

Pituitary gland function following craniocerebral trauma III° in younger patients

ea0026p218 | Pituitary

Macroprolactinomas in 38 children and adolescents: sex differences and long-term results of medical treatment

ea0026p219 | Pituitary

Medical treatment of an agressive non-secreting pituitary tumor and non-secreting pituitary carcinoma: a report of two cases

ea0026p220 | Pituitary

Normal pregnancy in a woman with history of panhypopituitarism due to lymphocytic hypophysitis

ea0026p221 | Pituitary

PANCH tumor in a female patient

ea0026p222 | Pituitary

On the effect of CRH and dexamethasone on Pomc synthesis and ACTH secretion in rat pituitary primary cultures

ea0026p223 | Pituitary

KIT protein expression and mutational status of KIT gene in pituitary adenomas

ea0026p224 | Pituitary

Long-term effects of radiotherapy on cardiovascular risk factors in acromegaly

ea0026p225 | Pituitary

Effect of GH as add-on treatment in severe fibromyalgia syndrome. Results from the IIIb, CT27560 placebo-controlled, multicenter trial

ea0026p226 | Pituitary

Tumor occurrence or recurrence after five year GH replacement theraphy

ea0026p227 | Pituitary

Pituitary function in type 2 diabetic men with good or poor glycaemic control

ea0026p228 | Pituitary

Non-traditional effects of GH: a survival factor for retinal ganglion cells

ea0026p229 | Pituitary

Clinical and subclinical apoplexy in nonfunctioning pituitary tumors: clinical features, management and outcome

ea0026p230 | Pituitary

Comparison of GH suppression response after oral and intravenous glucose tolerance tests in healthy subjects

ea0026p231 | Pituitary

The reliability of GH stimulation tests in the diagnosis of childhood GH deficiency

ea0026p232 | Pituitary

Copeptin in the differential diagnosis of the polydipsia–polyuria syndrome: revisiting the direct and indirect water deprivation tests

ea0026p233 | Pituitary

GH replacement therapy in elderly GH deficient patients: a systematic review

ea0026p234 | Pituitary

Does GH replacement therapy reduce mortality in adults with GH deficiency? Data from the Dutch National Registry of GH Treatment in adults

ea0026p235 | Pituitary

Hormonal effects on cardiovascular function in patients with acromegaly

ea0026p236 | Pituitary

Expression of canonical Wnt proteins and survivin in pituitary tumours

ea0026p237 | Pituitary

Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly

ea0026p238 | Pituitary

Improvement of acromegalic cardiomyopathy following pituitary apoplexy

ea0026p239 | Pituitary

Pituitary apoplexy as initial manifestation of pituitary tumors: two case reports

ea0026p240 | Pituitary

Detection of antipituitary antibodies using human and primate pituitary glands in patients with autoimmune thyroid disease and diabetes mellitus type 1

ea0026p241 | Pituitary

Periodontal disease ferquency in acromegalic patients

ea0026p242 | Pituitary

Relationship between GH activity and markers of inflammation: a cross-over study of healthy volunteers treated with GH and a GH antagonist for 3 weeks

ea0026p243 | Pituitary

Diabetes mellitus as adjunctive risk factor for vertebral fractures in men with acromegaly

ea0026p244 | Pituitary

Hyperprolactinemia is a risk factor for radiological vertebral fractures in post-menopausal women

ea0026p245 | Pituitary

Efficacy of weekly pegvisomant monotherapy

ea0026p246 | Pituitary

AcroBel-2: the Belgian follow-up survey on acromegaly: contribution of pituitary surgery and the use of pegvisomant to an improvement in disease control

ea0026p247 | Pituitary

A multicenter study on acromegalic patients treated with pegvisomant monotherapy or with pegvisomant plus somatostatin analogues: role of exon 3 deleted GH receptor polymorfism

ea0026p248 | Pituitary

Detection of acromegaly by automatic face classification software

ea0026p249 | Pituitary

Prolactinoma cell culture: experimental model for tumor growth

ea0026p250 | Pituitary

Evolution of invasive treatment-resistant prolactin (PRL) adenoma

ea0026p251 | Pituitary

Lost to follow-up in acromegaly, results of ACROSPECT observational study

ea0026p252 | Pituitary

Initial management and complications of Cushing disease (CD): a French multicenter study of 437 patients

ea0026p253 | Pituitary

The value of T2 weighted MR-imaging for stratification to medical therapy in newly diagnosed acromegaly

ea0026p254 | Pituitary

Lack of efficacy of 24-month treatment with the GH receptor antagonist pegvisomant in patient with active acromegaly resistant to long-term, high-dose somatostatin analog treatment: effects on IGF1 and GH levels

ea0026p255 | Pituitary

Quality of life and cortisol diurnal rhythm after 3 months of medical treatment for Cushing’s disease

ea0026p256 | Pituitary

Low incidence of adrenal insufficiency after transsphenoidal surgery in patients with acromegaly: a long-term follow-up study

ea0026p257 | Pituitary

Fertility rate in acromegalic women: a single center experience on 70 patients before and after treatment

ea0026p258 | Pituitary

Prevalence of germline mutations of AIP gene in sporadic aggressive somatotropinomas

ea0026p259 | Pituitary

Predictive markers of recurrence in radically resected pituitary macroadenomas

ea0026p260 | Pituitary

Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers

ea0026p261 | Pituitary

The efficacy of octreotide LAR in acromegalic patients

ea0026p262 | Pituitary

A novel AIP mutation related to familial isolated pituitary adenomas (FIPA)

ea0026p263 | Pituitary

Octreotide pharmacokinetics and biochemical control of acromegaly using a subcutaneous octreotide hydrogel implant

ea0026p264 | Pituitary

Transition to endoscopic transsphenoidal pituitary surgery: a single-center experience

ea0026p265 | Pituitary

Pasireotide (SOM230) demonstrates efficacy in patients with Cushing’s disease: results from a large, randomized-dose, double-blind, Phase III study

ea0026p266 | Pituitary

Clonality analysis of pituitary adenomas: a pilot study

ea0026p267 | Pituitary

Effect of gender and on the invasiveness of prolactinomas

ea0026p268 | Pituitary

Frequency of acute-onset symptoms and other features of craniopharyngioma presentation in children and adults

ea0026p269 | Pituitary

Macroprolactinomas and pregnancy: analysis of a 38-women cohort treated by dopamine agonists

ea0026p270 | Pituitary

Primary empty sella is associated with increased cardiovascular risk, regardless the occurrence of pituitary dysfunction

ea0026p271 | Pituitary

Evaluation of health-related quality of life in patients with Cushing’s disease and patients with non-functioning pituitary adenomas

ea0026p272 | Pituitary

Topoisomerase II α expression in human pituitary adenomas as the prognostic factor

ea0026p273 | Pituitary

Cyclooxygenase 2 expression in human pituitary adenomas

ea0026p274 | Pituitary

Recent changes in clinical presentation and therapeutic approach in MEN1-related pituitary adenomas

ea0026p275 | Pituitary

Prolactinoma and thyroid function

ea0026p276 | Pituitary

Late development of resistance to cabergoline in a giant macroprolactinoma with aggressive carvenous sinus and spheinodal bone invasion

ea0026p277 | Pituitary

Minimal active acromegaly may be effectively treated by prolonged injections of octreotide LAR

ea0026p278 | Pituitary

Radiological features of breast benign lesions in patients with hyperprolactinemia

ea0026p279 | Pituitary

A patient with ACTH-dependent Cushing’s syndrome and an unexpected neuropathogical diagnosis

ea0026p280 | Pituitary

Immunoglobulin G4-related infundibulo-hypophysitis: report of 4 cases and review of the literature

ea0026p281 | Pituitary

Assessment of retinopathy in acromegaly

ea0026p282 | Pituitary

Success rate of surgery in patients with macroprolactinoma

ea0026p283 | Pituitary

GH deficiency in cured acromegalic patients: metabolic effects of recombinant hGH replacement

ea0026p284 | Pituitary

Improvement in clinical signs and symptoms of Cushing’s disease following 12 months' pasireotide therapy

ea0026p285 | Pituitary

Pituitary calf transplantation into the human, 50 years after

ea0026p286 | Pituitary

The impact of transsphenoidal surgery on glucose homeostasis and insulin resistance in acromegaly

ea0026p287 | Pituitary

Tumor size and parasellar extension influence on macroprolactinomas’ outcome

ea0026p288 | Pituitary

Pegvisomant therapy in acromegaly: a multicenter observational study

ea0026p289 | Pituitary

ACTH-secreting pituitary adenomas express higher SSTR5 than SSTR2 protein levels by immunohistochenistry using new monoclonal antibodies against SST-binding domains

ea0026p290 | Pituitary

Cardiac risk in patients with treatment naïve, first-line medically controlled and first-line surgically cured acromegaly in comparison to matched data from the general population

ea0026p291 | Pituitary

GH receptor mRNA expression and the effect of pegvisomant on GH secretion by somatotroph pituitary adenomas

ea0026p292 | Pituitary

Carotenoids inhibits cell proliferation, arrest cell cycle and induces apoptosis in pituitary tumor cells

ea0026p293 | Pituitary

Prevalence of sleep apnea sindrome (SAS) in patients with acromegaly

ea0026p294 | Pituitary

Patients previously treated for nonfunctioning pituitary macroadenomas have disturbed sleep characteristics, circadian movement rhythm, and subjective sleep quality

ea0026p295 | Pituitary

The dual PI3K/mTOR inhibitor NVP-BEZ235 has a potent antiproliferative action in human nonfunctioning pituitary adenomas

ea0026p296 | Pituitary

Primary pituitary tumors: 10-year single center experience

ea0026p297 | Pituitary

Pituitary apoplexy: clinical characteristics, circumstances of diagnosis and evolution in a Romanian patient series

ea0026p298 | Pituitary

Effects of short (6 months) and long (18 months) term treatment with GH-receptor antagonist pegvisomant (PEG) on rhythm disturbances in acromegaly

ea0026p299 | Pituitary

Pituitary dysfunction types and clinical presentation of pituitary microadenomas in childhood and adolescence

ea0026p300 | Pituitary

Secondary erythrocytosis due to acromegaly

ea0026p301 | Pituitary

Patients with active acromegaly (AA) have less hepatic triglyceride than normal subjects using proton magnetic resonance spectroscopy (1H MRS)

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more